TipRanks
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
US Market
BMRN
BioMarin Pharmaceutical
RESEARCH TOOLSreports
Want to see BMRN full AI Analyst Report?

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

2,458 Followers
See the Price Targets and Ratings of:

BMRN Analyst Ratings

Strong Buy
22Ratings
Strong Buy
17 Buy
5 Hold
0 Sell
Based on 22 analysts giving stock ratings to
BioMarin
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BMRN Stock 12 Month Forecast

Average Price Target

$93.15
▲(40.88% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $93.15 with a high forecast of $124.00 and a low forecast of $60.00. The average price target represents a 40.88% change from the last price of $66.12.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"$52","125":"$125","70.25":"$70.3","88.5":"$88.5","106.75":"$106.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$124.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$93.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,70.25,88.5,106.75,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.84,69.39076923076924,73.94153846153847,78.49230769230769,83.04307692307692,87.59384615384616,92.14461538461538,96.69538461538461,101.24615384615385,105.79692307692308,110.34769230769231,114.89846153846153,119.44923076923077,{"y":124,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.84,67.01769230769231,69.19538461538463,71.37307692307692,73.55076923076923,75.72846153846154,77.90615384615386,80.08384615384617,82.26153846153846,84.43923076923078,86.61692307692309,88.79461538461538,90.97230769230771,{"y":93.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.84,64.46769230769232,64.09538461538462,63.723076923076924,63.35076923076923,62.97846153846154,62.606153846153845,62.23384615384616,61.861538461538466,61.48923076923077,61.11692307692308,60.744615384615386,60.37230769230769,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":59.09,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.74,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.03,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.82,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.02,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.84,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$124.00Average Price Target$93.15Lowest Price Target$60.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on BMRN
Jessica Fye
J.P. Morgan
J.P. Morgan
$86
Buy
30.07%
Upside
Reiterated
09/21/26
Analysts Conflicted on These Healthcare Names: Tilray (NASDAQ: TLRY) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Guggenheim Analyst forecast on BMRN
Debjit Chattopadhyay
Guggenheim
Guggenheim
$86
Buy
30.07%
Upside
Reiterated
09/17/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)
Morgan Stanley Analyst forecast on BMRN
Sean Laaman
Morgan Stanley
Morgan Stanley
$124
Buy
87.54%
Upside
Assigned
09/16/26
Morgan Stanley Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
BMO Capital Analyst forecast on BMRN
David Lebowitz
BMO Capital
BMO Capital
$98→$97
Buy
46.70%
Upside
Assigned
09/16/26
BioMarin price target lowered to $97 from $98 at BMO CapitalBioMarin price target lowered to $97 from $98 at BMO Capital
Citi Analyst forecast on BMRN
Eric Joseph
Citi
Citi
―
Buy
―
Reiterated
09/14/26
Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), BioMarin Pharmaceutical (BMRN)
Wells Fargo Analyst forecast on BMRN
Mohit Bansal
Wells Fargo
Wells Fargo
$80
Buy
20.99%
Upside
Reiterated
09/11/26
Analysts Offer Insights on Healthcare Companies: AxoGen (NASDAQ: AXGN) and BioMarin Pharmaceutical (NASDAQ: BMRN)
H.C. Wainwright Analyst forecast on BMRN
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$60
Hold
-9.26%
Downside
Reiterated
09/10/26
BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged
Piper Sandler Analyst forecast on BMRN
Allison Bratzel
Piper Sandler
Piper Sandler
$88→$90
Buy
36.12%
Upside
Reiterated
09/01/26
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), BioMarin Pharmaceutical (NASDAQ: BMRN) and Envista Holdings (NYSE: NVST)
Cantor Fitzgerald Analyst forecast on BMRN
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$85→$86
Buy
30.07%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Karyopharm Therapeutics (NASDAQ: KPTI)
Jefferies Analyst forecast on BMRN
Akash Tewari
Jefferies
Jefferies
$104→$105
Buy
58.80%
Upside
Reiterated
08/31/26
Analyst Sees BioMarin Undervalued After Ascendis Settlement, Modestly Raising Price Target to $105
Canaccord Genuity Analyst forecast on BMRN
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$114
Buy
72.41%
Upside
Reiterated
08/31/26
BioMarin Settlement with Ascendis Clears Legal Overhang; Analyst Reaffirms Buy Rating and Maintains $114 Price Target
William Blair Analyst forecast on BMRN
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
08/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and BridgeBio Pharma (NASDAQ: BBIO)
Stifel Nicolaus Analyst forecast on BMRN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$70
Hold
5.87%
Upside
Reiterated
08/31/26
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Ionis Pharmaceuticals (NASDAQ: IONS)
Goldman Sachs Analyst forecast on BMRN
Salveen Richter
Goldman Sachs
Goldman Sachs
$70
Hold
5.87%
Upside
Reiterated
08/31/26
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
TD Cowen Analyst forecast on BMRN
Phil Nadeau
TD Cowen
TD Cowen
$120
Buy
81.49%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on BMRN
Jessica Fye
J.P. Morgan
J.P. Morgan
$86
Buy
30.07%
Upside
Reiterated
09/21/26
Analysts Conflicted on These Healthcare Names: Tilray (NASDAQ: TLRY) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Guggenheim Analyst forecast on BMRN
Debjit Chattopadhyay
Guggenheim
Guggenheim
$86
Buy
30.07%
Upside
Reiterated
09/17/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)
Morgan Stanley Analyst forecast on BMRN
Sean Laaman
Morgan Stanley
Morgan Stanley
$124
Buy
87.54%
Upside
Assigned
09/16/26
Morgan Stanley Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
BMO Capital Analyst forecast on BMRN
David Lebowitz
BMO Capital
BMO Capital
$98→$97
Buy
46.70%
Upside
Assigned
09/16/26
BioMarin price target lowered to $97 from $98 at BMO CapitalBioMarin price target lowered to $97 from $98 at BMO Capital
Citi Analyst forecast on BMRN
Eric Joseph
Citi
Citi
―
Buy
―
Reiterated
09/14/26
Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), BioMarin Pharmaceutical (BMRN)
Wells Fargo Analyst forecast on BMRN
Mohit Bansal
Wells Fargo
Wells Fargo
$80
Buy
20.99%
Upside
Reiterated
09/11/26
Analysts Offer Insights on Healthcare Companies: AxoGen (NASDAQ: AXGN) and BioMarin Pharmaceutical (NASDAQ: BMRN)
H.C. Wainwright Analyst forecast on BMRN
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$60
Hold
-9.26%
Downside
Reiterated
09/10/26
BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged
Piper Sandler Analyst forecast on BMRN
Allison Bratzel
Piper Sandler
Piper Sandler
$88→$90
Buy
36.12%
Upside
Reiterated
09/01/26
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), BioMarin Pharmaceutical (NASDAQ: BMRN) and Envista Holdings (NYSE: NVST)
Cantor Fitzgerald Analyst forecast on BMRN
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$85→$86
Buy
30.07%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Karyopharm Therapeutics (NASDAQ: KPTI)
Jefferies Analyst forecast on BMRN
Akash Tewari
Jefferies
Jefferies
$104→$105
Buy
58.80%
Upside
Reiterated
08/31/26
Analyst Sees BioMarin Undervalued After Ascendis Settlement, Modestly Raising Price Target to $105
Canaccord Genuity Analyst forecast on BMRN
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$114
Buy
72.41%
Upside
Reiterated
08/31/26
BioMarin Settlement with Ascendis Clears Legal Overhang; Analyst Reaffirms Buy Rating and Maintains $114 Price Target
William Blair Analyst forecast on BMRN
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
08/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and BridgeBio Pharma (NASDAQ: BBIO)
Stifel Nicolaus Analyst forecast on BMRN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$70
Hold
5.87%
Upside
Reiterated
08/31/26
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Ionis Pharmaceuticals (NASDAQ: IONS)
Goldman Sachs Analyst forecast on BMRN
Salveen Richter
Goldman Sachs
Goldman Sachs
$70
Hold
5.87%
Upside
Reiterated
08/31/26
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
TD Cowen Analyst forecast on BMRN
Phil Nadeau
TD Cowen
TD Cowen
$120
Buy
81.49%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
LFMDLifeMD
ORKAOruka Therapeutics
ACHVAchieve Life Sciences
PLSEPulse Biosciences
PMNProMIS Neurosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months
Christopher RaymondRaymond James
Success Rate
16/36 ratings generated profit
44%
Average Return
-0.10%
Copying Christopher Raymond's trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -0.10% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
22/43 ratings generated profit
51%
Average Return
-2.81%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 51.16% of your transactions generating a profit, with an average return of -2.81% per trade.
2 Years
Phil NadeauTD Cowen
Success Rate
16/26 ratings generated profit
62%
Average Return
-1.35%
Copying Phil Nadeau's trades and holding each position for 2 Years would result in 61.54% of your transactions generating a profit, with an average return of -1.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMRN Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
27
26
25
16
17
Buy
11
6
7
10
17
Hold
10
10
13
14
15
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
48
42
45
40
49
In the current month, BMRN has received 34 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the past 3 months is 93.15.
Each month's total comprises the sum of three months' worth of ratings.

BMRN Financial Forecast

BMRN Earnings Forecast

Next quarter’s earnings estimate for BMRN is $1.33 with a range of $1.22 to $1.48. The previous quarter’s EPS was $1.20. BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.
Next quarter’s earnings estimate for BMRN is $1.33 with a range of $1.22 to $1.48. The previous quarter’s EPS was $1.20. BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Sales Forecast

Next quarter’s sales forecast for BMRN is $1.02B with a range of $1.00B to $1.05B. The previous quarter’s sales results were $996.38M. BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.
Next quarter’s sales forecast for BMRN is $1.02B with a range of $1.00B to $1.05B. The previous quarter’s sales results were $996.38M. BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Stock Forecast FAQ

What is BMRN’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 93.15.
    What is BMRN’s upside potential, based on the analysts’ average price target?
    BioMarin Pharmaceutical has 40.88% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BMRN a Buy, Sell or Hold?
          BioMarin Pharmaceutical has a consensus rating of Strong Buy which is based on 17 buy ratings, 5 hold ratings and 0 sell ratings.
            What is BioMarin Pharmaceutical’s price target?
            The average price target for BioMarin Pharmaceutical is 93.15. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $124.00 ,the lowest forecast is $60.00. The average price target represents 40.88% Increase from the current price of $66.12.
              What do analysts say about BioMarin Pharmaceutical?
              BioMarin Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of BMRN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.